News
For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.
17th
Nov 21
Pharmaxis Announces A$7.2m Placement and A$2.0m Share Purchase Plan
Highlights:
- A$7.2m being raised in an oversubscribed placement to institutional and sophisticated investors
- Strong support from existing major shareholders together with new institutional shareholders joining the register
- Strong pro-forma cash balance post raising
- Strengthened balance sheet to support next phase of clinical trials in bone cancer, liver cancer and wound and burns scarring
- Issue price of A$0.105 represents a 12.0% discount to the 5-day VWAP of $0.119
- Share purchase plan to raise approximately $2.0 million to eligible shareholders
9th
Nov 21
FDA Clears Pharmaxis Cancer Drug to Progress to Phase 2 Study in Liver Cancer
- IND approved to trial PXS-5505 added to current standard of care in newly diagnosed unresectable hepatocellular carcinoma patients
- University of Rochester Medical Center and Pharmaxis in discussions to commence investigator-led study in 2022